News

   ABX-CRO is proud to announce the friendly acquisition of ClinSmart LLC (Pennsylvania, USA), a well-established clinical quality CRO. This transaction represents a major milestone in ABX-CRO’s continued growth and the expansion of its global service portfolio....

A major milestone for ABX-CRO!  We are now an officially registered and accredited Radiopharmaceutical CRO with CDSCO in India specialized in radiopharmaceutical clinical trials. This marks an important step in expanding our global footprint and strengthening our...

ABX-CRO and ITM (Isotope Technologies Munich) win the prestigious Marie Curie Award of the EANM for outstanding research contributions in nuclear medicine: Dosimetry of the COMPETE study (ITM-11 (n.c.a. 177Lu-DOTATOC) in GEP-NET) The COMPETE (Controlled, Open-label,...

We are grateful for our team’s dedication and this significant achievement. ABX-CRO is proud to announce the successful completion of an FDA pre-approval inspection for a PET radiodiagnostic with a biological pharmacophore of a global phase III trial conducted by...

ABX-CRO  wholeheartedly congratulates ITM (Isotope Technologies Munich) to the successful outcome of the COMPETE study (ITM-11 (n.c.a. 177Lu-DOTATOC)  in GEP-NET) The success of COMPETE, marks another milestone in ABX-CRO´s unique track record designing and conducting...

The scientific and commercial members of the globally unique radiopharmaceutical competence cluster Dresden/Radeberg (Saxony, Germany), comprehensively covering the entire radiopharmaceutical value creation chain from targetry, discovery over R & D, manufacturing,...

In 2025 we would like to take the opportunity to welcome our new employee in India: Dr. Rakhee Vatsa! She has started at ABX-CRO India in September 2024 as Technical Head CDMO. Since then she has been awarded the Distinguished Alumnus Award on Dec 21, 2024 by the...

We are extremely proud that our central involvement in designing, execution and analysis of of the Telix ZIRCON pivotal phase III study was recently recognised in The Lancet Group Oncology. This prospective, open-label, multicentre study evaluated the clinical utility...

This summer we welcome our first two trainees. We look forward to seeing them learn and grow!!

We are proud to announce that the dosimetry software QDOSE® designed by us and our development partner Quantinm AB will now become part of a commercial partnership with Telix. Telix intends to integrate the platform into its therapeutic radiopharmaceutical programmes...